Cyclic Tetrapeptide KOR Antagonists for Addiction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for addiction, particularly cocaine and other drug addictions, face challenges due to side effects from small molecules interacting with unintended receptors, and existing kappa-opioid receptor (KOR) antagonists are unstable and unsuitable for systemic administration.
Innovation Solution
Development of stable cyclic tetrapeptide KOR antagonists and agonists that selectively target KOR, allowing for effective treatment of addiction and related behaviors by crossing the blood-brain barrier, with improved selectivity and metabolic stability compared to small molecule and polypeptide antagonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules are used as KOR antagonists, then they can effectively block kappa-opioid receptor activity, but they cause negative side effects by cross-interacting with unintended receptors
Solution Approach 1:
The patent segments the opioid receptor family targeting by designing peptide compounds that specifically interact with KOR while avoiding other opioid receptors. The cyclic tetrapeptide structure allows selective binding to KOR through specific amino acid sequences (Trp-Phe-D-Pro-Phe) that match the KOR binding pocket, thereby achieving receptor selectivity and reducing side effects from cross-interaction with other receptors.
Solution Approach 2:
The patent applies local quality by optimizing specific regions of the peptide structure. The cyclic tetrapeptide configuration with specific amino acid residues at defined positions creates a localized binding interface that is highly selective for KOR. The D-Pro and Phe residues provide specific interaction sites that confer KOR selectivity without affecting other receptor types, thus reducing harmful side effects.
2Reliability
If polypeptide KOR antagonists are used, then they can provide selective KOR antagonism, but they are unstable and unsuitable for systemic administration
Solution Approach 1:
The patent extracts the essential functional elements from longer polypeptide structures and condenses them into a cyclic tetrapeptide framework. By removing excess amino acid residues while maintaining the core Trp-Phe-D-Pro-Phe sequence necessary for KOR binding, the compound achieves both selectivity and improved stability. The cyclic structure eliminates free N- and C-termini, protecting against proteolytic degradation while retaining biological activity.
Solution Approach 2:
The patent creates a composite structure combining peptide bonds with a cyclic configuration. This cyclic tetrapeptide composite structure provides enhanced metabolic stability compared to linear peptides while maintaining KOR selectivity. The closed ring structure reduces conformational flexibility and protects against enzymatic degradation, making the compound suitable for systemic administration.
3Reliability
If existing KOR antagonists are used, then they can treat addiction-related behaviors, but they have long duration of action causing prolonged side effects
Solution Approach 1:
The patent employs a short-lived peptide compound that rapidly clears from the system after performing its therapeutic function. The cyclic tetrapeptide KOR antagonist provides sufficient receptor blocking during the critical window for preventing drug-seeking behavior, then quickly metabolizes to eliminate prolonged side effects. This short duration of action is achieved through the peptide's inherent metabolic stability balanced by controlled clearance, avoiding the need for long-acting formulations.
Data Source
AI summary
Cyclic tetrapeptides that are kappa opioid receptor (KOR) antagonists can be used in therapeutic applications for treating, inhibiting, and/or preventing drug addiction, drug use, or drug seeking behavior in a subject. This can include subjects that have a history of drug addiction. The drug can be selected from cocaine, alcohol, amphetamines, methamphetamines, nicotine, opiate, or combinations thereof. These cyclic tetrapeptides can also be useful for treating, inhibiting, and/or preventing stress-induced drug seeking behavior.